Extranodal diffuse large B-cell lymphoma with monoclonal gammopathy: an aggressive and primary refractory disease responding to an immunomodulatory agent

BACKGROUND: Although the clinical outcome of patients with diffuse large B cell lymphoma (DLBCL) has been improved by the addition of rituximab to standard chemotherapy, almost one-third fails or relapses after first line treatment. The presence of monoclonal gammopathy (MG) is a known adverse progn...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Exp Hematol Oncol
Glavni autori: Mondello, Patrizia, Pitini, Vincenzo, Barresi, Valeria, Brea, Elliott Joseph, Di Mirto, Cristian, Arrigo, Carmela, Cuzzocrea, Salvatore, Mian, Michael
Format: Artigo
Jezik:Inglês
Izdano: BioMed Central 2016
Teme:
Case Report
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4702294/
https://ncbi.nlm.nih.gov/pubmed/26740908
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40164-015-0030-1
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items